Medicare GLP-1 Bridge program reaches roughly 600,000 enrollees by end of August, about 15% of eligible beneficiaries
Sep 12, 2026 – Sep 26, 2026
-
Medicare GLP-1 Bridge demonstration live since July 1 with $50 monthly copay and no published enrollment data
CMS's GLP-1 Bridge demonstration went live July 1, 2026, covering Wegovy, Zepbound, and Foundayo at a flat $50 monthly copay for qualifying Medicare Part D enrollees through December 31, 2027, while CMS has not released any uptake figures and FDA has not yet finalized a rule barring large-scale compounding of semaglutide and tirzepatide.
Read this issue → -
Medicare GLP-1 Bridge program reaches roughly 600,000 enrollees by end of August, about 15% of eligible beneficiaries
CMS confirmed at an August 31 briefing that enrollment in the GLP-1 Bridge demonstration reached approximately 600,000 Medicare beneficiaries, up from about 250,000 in July, covering obesity-diagnosed enrollees who receive Wegovy, Zepbound, or Foundayo at a $50 monthly copay, while an estimated 5.9 million additional Medicare enrollees with GLP-1-relevant diagnoses remain on standard Part D cost sharing.
Read this issue →